Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

SCREENING OF EPIGENETIC BIOMARKERS (miRNAs) IN THE GINGIVAL SULCUS

26 de abril de 2018 atualizado por: ANA FUENMAYOR GARCÉS, University of Valencia

Screening of Epigenetic Biomarkers (miRNA) in the Gingival Sulcus

Epigenetics has produced a high impact in biomedical research and is providing new biomarkers for the diagnosis and prognosis of diseases. In addition, epigenetics is also contributing to analyze the molecular causes underlying diseases, even so periodontal diseases as it has been recently reviewed. In this regard, changes in the methylation of genes codifying for pro-inflammatory and anti-inflammatory cytokines has been previously reported. miRNAs are very promising biomolecules to be used as biomarkers because miRNAs act as signaling molecules and participate in many biological processes, such as cellular development, differentiation, and apoptosis. The high stability of circulating miRNAs in the RNase-rich environment of the bloodstream and also in different biospecimens used in clinical routine, make these biomolecules an optimal source of candidate biomarkers. In fact, miRNAs have demonstrated their value as dynamic biomarkers in a wide variety of human diseases. Therefore, miRNAs can be used for the monitoring of periodontal disease.

The objective of this research is to analyze the levels of bone remodeling RANKL / OPG biomolecular markers, and the epigenetic regulation of these proteins to identify promising biomarkers of periodontal disease.

Material and Methods. Levels of RANKL and OPG will be measured in the gingival crevicular fluid (GCF) to assess the state of bone. These samples will be sent to the lab for quantification by ELISA method.

Furthermore, new epigenetic biomarkers based on the identification of high stable microRNAs will be identified by qRT-PCR in GCF as feasible tools for diagnosis and monitoring of wide range of disease, including periodontal disease.

Visão geral do estudo

Tipo de estudo

Observacional

Inscrição (Antecipado)

40

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Valencia, Espanha
        • Recrutamento
        • Ana Fuenmayor Garcés
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

30 anos a 60 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Patients attending to the university who meet the inclusion criteria.

Descrição

Inclusion Criteria:

Group of periodontal patients:

  1. Clinical criteria: at least 3 locations in unirradicular teeth with PD 6 mm. 3 samples will be taken from each of these 3 locations (9 total samples). Third molars are not included in the study.
  2. Patients not treated periodontally.
  3. 30-60 years.

Periodontally healthy group:

1. Absence of clinical and radiographical periodontal pathology.

Exclusion Criteria:

  • Group of periodontal patients:

    1. Aggressive Periodontal Disease (Armitage, 1999).
    2. Patients with controlled periodontal disease with plaque and gingival indexes ≤20%.
    3. Patients with systemic diseases or taking medications that alter bone metabolism (Osteoporosis, arthritis, hormonal treatment, bisphosphonates, anti-inflammatory, immunosuppressants, etc ...).
    4. Patients with antibiotic, anti-inflammatory or contraceptive treatment in the previous 3 months or taking antiaggregants in the last 7 days before taking the sample.
    5. Smokers (> 10 cig. /day).
    6. Pregnant or breast-feeding.

Periodontally healthy group:

  1. Patients with systemic diseases or taking medications that alter bone metabolism (Osteoporosis, arthritis, hormonal treatment, bisphosphonates, anti-inflammatory, immunosuppressant...).
  2. Patients with antibiotic, anti-inflammatory or contraceptive treatment in the previous 3 months or taking antiaggregants in the last 7 days before taking the sample.
  3. Smokers (> 10 cig/day).
  4. Pregnant or breast-feeding.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Periodontal patients.
Taking gingival Crevicular fluid.

Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.

Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers.

Periodontally healthy patients.
Taking gingival Crevicular fluid.

Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.

Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
microRNA in gingival crevicular fluid (physiological parameter).
Prazo: 2 years.
Insert the Perio Paper® tip in gingival sulcus until resistance is felt and leave it for 30 seconds.
2 years.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Probing depth.
Prazo: 2 years.
Probing depth will be measured in six sites (disto-buccal, mid-buccal, mesio-buccal, disto-palatal, mid-palatal and mesio- palatal) of every teeth with a Williams Probe PQ-OW 208 396. This probe is used by gently hanging pressure into a pocket measuring 20 grams in weight.
2 years.
Bleeding on probing.
Prazo: 2 years.
Full mouth bleeding score (FMBS) will be calculated based on scores of 0 (no bleeding) or 1 (bleeding) after probing for PD. The usual thing to do is to measure at 4 points for each tooth but we have modified the index and we valorate them at 6 points. (disto-buccal, mid-buccal, mesio-buccal, disto-palatal, mid-palatal and mesio- palatal).
2 years.
Clinical recession.
Prazo: 2 years.
Clinical recession will be measured in the same six sites as before between the Amelocemental junction and the gingival margin.
2 years.
Plaque score of Silness y löe: (1964)
Prazo: 2 years.

The Plaque will be scored as follows:

Score 0 = No plaque

Score 1 = A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may be seen in situ only after application of disclosing solution or by using the probe on the tooth surface.

Score 2 = Moderate accumulation of soft deposits within the gingival pocket, or on the tooth and gingival margin, which can be seen with the naked eye.

Score 3 = Abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin.

The usual thing to do is to evaluate at 4 points for each tooth but we have modified the index and we will evaluate at 6 points. (disto-buccal, mid-buccal, mesio-buccal, disto-palatal, mid-palatal and mesio- palatal)

2 years.
Dental movility of Mïller 1950
Prazo: 2 years.

Class I

Up to 1 mm of movement in a horizontal direction.

Class II Greater than 1 mm of movement in a horizontal direction. Class III

Excessive horizontal movement and vertical movement.

2 years.
Furcation affection.
Prazo: 2 years.

Class I:

The level of bone loss allows for the insertion of the periodontal Nabers probe into the concavity of the root trunk. Furcation defect is less than 3 mm is depth.

Class II The level of bone loss allows for the insertion of a periodontal probe into the furcation area between the roots. Furcation defect is at least 3 mm in depth (and thus, in general, surpassing half of the buccolingual thickness of the tooth) but not through-and-through (i.e. there is still some interradicular bone attached to the angle of the furcation.

15

Class III The level of bone loss allows for "through and through" access of the furcation area. Buccal to lingual on lower molars. Buccal to mesio-palatal and disto-palatal on upper molars. Furcation defect encompassing the entire width of the tooth so that no bone is attached to the angle of the furcation.

2 years.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

15 de setembro de 2017

Conclusão Primária (Antecipado)

1 de julho de 2019

Conclusão do estudo (Antecipado)

1 de julho de 2019

Datas de inscrição no estudo

Enviado pela primeira vez

1 de abril de 2018

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de abril de 2018

Primeira postagem (Real)

27 de abril de 2018

Atualizações de registro de estudo

Última Atualização Postada (Real)

27 de abril de 2018

Última atualização enviada que atendeu aos critérios de controle de qualidade

26 de abril de 2018

Última verificação

1 de abril de 2018

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • H1510580113419

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Doenças Periodontais

3
Se inscrever